Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY-SET-HAPLO: Sequential Chemotherapy and RIC Haplo-HSCT in Lymphoid Disorders
NCT03079089Completed
- Start
- Jun 2017
- Primary completion
- Sep 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of donor lymphocytes in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and 2 more. Primary endpoint: Overall Survival at 2 years. Started Jun 2017; status: completed.
02
Drugs
donor lymphocytes
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)Waldenstrom macroglobulinemia (WM)prolymphocytic leukemia (PLL)
Beyond the preview
Go deeper on NCT03079089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03079089.